JPMorgan downgraded Novavax to Underweight from Neutral with an unchanged price target of $8. The shares are up 267% since the announced strategic partnership with Sanofi for Novavax’s COVID-19 vaccine program, the analyst tells investors in a research note. The firm believes current share levels “substantially overvalue” the potential Nuvaxovid economics and revenue to Novavax. JPMorgan sees Covid vaccine demand ultimately being fractional to that of flu.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax call volume above normal and directionally bullish
- Novavax price target lowered to $31 from $38 at Jefferies
- Unusually active option classes on open July 15th
- Novavax’s (NASDAQ:NVAX) Pullback Could Signal a Buying Opportunity
- Novavax submits application to EMA for updated JN.1 COVID-19 vaccine
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue